What happened
Xcell Therapeutics filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$1.37M (+778% year on year), an operating loss of US$1.89M and a net loss of US$1.97M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$1.37M |
|---|---|
| Revenue vs a year earlier | +778% |
| Operating profit | −US$1.89M |
| Net income | −US$1.97M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-08-06, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260806900303 → open original filing |
Source: DART. Information only, not investment advice.